Breaking News

Tweet TWEET

Infinity Expands Executive Leadership Team, Appointing David A. Roth as Senior Vice President, Clinical Development and Medical

  Infinity Expands Executive Leadership Team, Appointing David A. Roth as
  Senior Vice President, Clinical Development and Medical Affairs

Business Wire

CAMBRIDGE, Mass. -- September 4, 2013

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the appointment
of David A. Roth, M.D., as senior vice president, clinical development and
medical affairs. In this newly created role, Dr. Roth will have responsibility
for the clinical development organization and clinical operations, and he will
also build and oversee the medical affairs function. Dr. Roth will serve as a
member of Infinity’s executive leadership team and will report to Pedro
Santabarbara, M.D., Ph.D., the company’s chief medical officer. Dr. Roth
brings to Infinity over 20 years of experience in hematology and oncology
research and development.

“It’s a pleasure to welcome David to Infinity. He holds a distinguished track
record spanning both industry and academia. His appointment substantially
enhances the depth and breadth of Infinity’s hematology and oncology expertise
as we rapidly advance our lead program, IPI-145, toward late-stage development
and potential registration,” stated Dr. Santabarbara. “David’s experience
encompasses both early-stage and registration-phase programs, and the Infinity
team looks forward to his contributions as we work to advance and expand our
pipeline.”

“Infinity’s PI3K-delta,gamma inhibitor, IPI-145, has the potential to help
transform the treatment landscape for patients with hematologic malignancies,
and I am pleased to join Infinity at such an exciting time,” commented Dr.
Roth. “Infinity has a history grounded in science and academic collaborations,
and I’m delighted to be a part of this team as we strive to bring important
new treatment options to patients and their physicians.”

Dr. Roth joins Infinity following more than ten years with Pfizer Inc. and
Wyeth Pharmaceuticals. At Pfizer, he most recently served as a vice president
in Pfizer’s oncology business unit. Dr. Roth joined Pfizer from Wyeth, where
he held the role of assistant vice president, clinical research & development
and global therapeutic area director of hematology. While at Pfizer and Wyeth,
Dr. Roth contributed to the successful regulatory approval of several
products, including Bosulif^® (bosutinib), a dual Src/Abl tyrosine kinase
inhibitor for the treatment of chronic myelogenous leukemia, Xyntha^® and
ReFacto AF^® for the treatment of hemophilia A, and BeneFIX^® for the
treatment of hemophilia B. Dr. Roth also led the early development of
palbociclib, a CDK 4/6 inhibitor, to Phase 3 evaluation in women with ER
positive advanced breast cancer. During his tenure at Pfizer and Wyeth, Dr.
Roth also co-chaired Pfizer’s oncology research and development board and
served on several oncology and hematology R&D leadership teams and governance
committees.

In addition to his extensive industry experience, Dr. Roth is an accomplished
academic researcher and clinical practitioner. He received his B.S. from the
Massachusetts Institute of Technology and his M.D. from Harvard Medical School
in the Harvard-M.I.T. Division of Health Sciences and Technology where he
remains on the Affiliated Faculty.

About Infinity Pharmaceuticals, Inc.

Infinity is an innovative biopharmaceutical company dedicated to discovering,
developing and delivering best-in-class medicines to people with
difficult-to-treat diseases. Infinity combines proven scientific expertise
with a passion for developing novel small molecule drugs that target emerging
disease pathways. Infinity’s programs focused on the inhibition of
phosphoinositide-3-kinase and heat shock protein 90 are evidence of its
innovative approach to drug discovery and development. For more information on
Infinity, please refer to the company’s website at www.infi.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding the company’s expectations about: the
expected responsibilities of Dr. Roth; the advancement of IPI-145 toward
late-stage development and potential registration; and the therapeutic
potential of its PI3K inhibitors. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events or
results to differ materially from the company’s current expectations. For
example, there can be no guarantee that Infinity will initiate clinical trials
or report data in the time frames it has estimated, that any product candidate
Infinity is developing will successfully complete necessary preclinical and
clinical development phases or that development of any of Infinity’s product
candidates will continue. Further, there can be no guarantee that any positive
developments in Infinity’s product portfolio will result in stock price
appreciation. Management’s expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks and
uncertainties relating to a number of other factors, including the following:
Infinity’s results of clinical trials and preclinical studies, including
subsequent analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the U.S. FDA and
other regulatory authorities, investigational review boards at clinical trial
sites and publication review bodies; Infinity’s ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its clinical trials;
unplanned cash requirements and expenditures; development of agents by
Infinity’s competitors for diseases in which Infinity is currently developing
its product candidates; and Infinity’s ability to obtain, maintain and enforce
patent and other intellectual property protection for any product candidates
it is developing. These and other risks which may impact management’s
expectations are described in greater detail under the caption “Risk Factors”
included in Infinity’s quarterly report on Form 10-Q filed with theSecurities
and Exchange Commission (SEC) onAugust 8, 2013, and other filings filed by
Infinity with theSEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Infinity expressly disclaims any
obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.

Bosulif^® and Xyntha^® are registered trademarks of Wyeth LLC. ReFacto AF^®
and BeneFIX^® are registered trademarks of Genetics Institute, LLC.

Contact:

Infinity Pharmaceuticals, Inc.
Jaren Irene Madden, 617-453-1336
Jaren.Madden@infi.com
http://www.infi.com
 
Press spacebar to pause and continue. Press esc to stop.